Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents
Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents
复制标题
DOI：
10.1080/17476348.2017.1361323
复制
发表时间：
2017-01-01
影响因子：
3.9
通讯作者：
Gray, Jhanelle E.
中科院分区：
文献类型：
--
作者：
Puri, Sonam;Chatwal, Monica;Gray, Jhanelle E.
肺癌是世界上最常见的癌症相关死亡原因。尽管最近取得了进展，但估计5年总生存率仅为17%左右。迫切需要开发新的有效的药物策略来治疗晚期肺癌。涵盖领域：本文综述了正在进行的免疫和非免疫肿瘤联合治疗非小细胞肺癌（NSCLC）的研究。在这里，我们将重点关注PD-L1抑制剂（免疫疗法）与化疗、血管内皮生长因子抑制剂、靶向治疗和放疗的联合应用。专家评论：免疫疗法是治疗非小细胞肺癌的一项重大进展，因为它具有持久的反应和总体有利的毒性。然而，这些反应只出现在一小部分患者中。对这种疗法的耐药性机制不断出现。联合治疗的研究正在进行中，因为这些药物的治疗机制不仅有明显的不同，而且与免疫治疗有协同作用。总的来说，已经注意到一些益处，尽管也显示出相关的毒性，并且包括总体生存在内的长期益处尚未确定。
Introduction: Lung cancer is the most common cause of cancer-related deaths in the world. Despite recent advances, the estimated 5-year overall survival is only around 17%. There is an urgent need for development of new effective drug strategies for the treatment of advanced-stage lung cancer.Areas covered: This review focuses on ongoing research in immune and non-immune oncology combinations for the treatment of non-small cell lung cancer (NSCLC). Here, we will focus on the combination of PD-L1 inhibitors (immunotherapy) with chemotherapy, vascular endothelial growth factor inhibitors, targeted therapies, and radiation.Expert commentary: Immunotherapy is a major advancement in the treatment of NSCLC due to its durable responses and overall favorable toxicity profile. However, these responses are seen in only a subset of patients. Mechanisms of resistance to this therapy continue to emerge. Studies on combination therapies are underway as the therapeutic mechanisms of these established agents are not only distinctly different but also synergistic with immunotherapy. Overall, some benefits have been noted, although associated toxicities have also been shown, and the long-term benefits including overall survival have yet to be determined.